Xponance Inc. Has $4.68 Million Holdings in STERIS plc $STE

Xponance Inc. trimmed its holdings in shares of STERIS plc (NYSE:STE) by 11.1% in the third quarter, HoldingsChannel reports. The firm owned 18,929 shares of the medical equipment provider’s stock after selling 2,360 shares during the period. Xponance Inc.’s holdings in STERIS were worth $4,684,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of STE. Jones Financial Companies Lllp grew its holdings in shares of STERIS by 46.1% during the first quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock worth $251,000 after purchasing an additional 349 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in STERIS by 32.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock worth $55,015,000 after buying an additional 59,264 shares in the last quarter. Empowered Funds LLC grew its holdings in STERIS by 16.1% during the 1st quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock worth $522,000 after acquiring an additional 319 shares during the last quarter. Woodline Partners LP grew its holdings in STERIS by 40.0% during the 1st quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock worth $1,881,000 after acquiring an additional 2,372 shares during the last quarter. Finally, Jane Street Group LLC increased its position in STERIS by 38.9% in the 1st quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock valued at $4,695,000 after acquiring an additional 5,803 shares in the last quarter. Institutional investors own 94.69% of the company’s stock.

STERIS Stock Down 0.9%

Shares of STERIS stock opened at $252.36 on Monday. The company has a quick ratio of 1.75, a current ratio of 2.48 and a debt-to-equity ratio of 0.26. STERIS plc has a 12 month low of $204.90 and a 12 month high of $269.44. The stock has a market cap of $24.75 billion, a PE ratio of 35.20 and a beta of 1.05. The business has a fifty day simple moving average of $255.83 and a 200 day simple moving average of $251.77.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.During the same period in the previous year, the firm posted $2.32 earnings per share. The company’s revenue for the quarter was up 9.2% on a year-over-year basis. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Research analysts predict that STERIS plc will post 9.08 EPS for the current year.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Investors of record on Tuesday, February 17th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, February 17th. STERIS’s dividend payout ratio (DPR) is presently 35.15%.

Wall Street Analyst Weigh In

STE has been the topic of a number of research reports. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Wall Street Zen downgraded STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, STERIS presently has a consensus rating of “Moderate Buy” and a consensus target price of $275.20.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.